Connect with us

Public Companies

Braxia Reports Promising Results for In-House Study of IV Ketamine on Ultra Resistant Depression

The post Braxia Reports Promising Results for In-House Study of IV Ketamine on Ultra Resistant Depression appeared first on Microdose.

In another victory…

Published

on

The post Braxia Reports Promising Results for In-House Study of IV Ketamine on Ultra Resistant Depression appeared first on Microdose.

In another victory for ketamine as an emerging mental health therapeutic, the team at Braxia Scientific recently completed their clinical trials utilizing IV ketamine for the treatment of ultra-resistant depression. In the study, subjects received four ketamine infusions, at subanesthetic doses, over two weeks at the Canadian Rapid Treatment Center (CRTCE). The results demonstrated that IV ketamine offers rapid and robust antidepressants, anti-suicidal and anxiolytic effects, and improved subjective function. With a large cohort size of 213 subjects and a p-value less than 0.005, these are exactly the kind of results their team was hoping for.

The Antidepressant Effectiveness in the Real World is Very Similar to the Antidepressant Efficacy in Braxia’s Clinical Trials

The big question the Braxia team was asking was whether or not their findings were generalizable to the real world. Essentially, is the antidepressant efficacy seen in clinical trials equivalent to the real-world effectiveness we see in our clinics? In his presentation, Dr. Joshua D. Rosenblat of Braxia states their findings demonstrated exactly that. Also interesting to hear about was Dr. Rosenblat stated that patients were able to come off disability and return to work thanks to this treatment. With both symptomatic and functional improvements demonstrated during these trials, ketamine is truly proving itself to be the robust therapeutic it’s promised to be.

IV Ketamine Also Shows Great Efficacy in Bipolar Treatment-Resistant Depression

IV Ketamine Also Shows Great Efficacy in Bipolar Treatment-Resistant Depression

Also worth noting was Braxia’s findings into IV ketamine for bipolar treatment-resistant depression, a very malignant form of depression that’s notoriously hard to treat. Interestingly enough, the Braxia team found IV ketamine especially useful in using ketamine infusions in the treatment of bipolar TRD. Finally, the risk of treatment-emergent hypomania was under 5%, especially if mood stabilizers were used.

What About Esketamine Nasal Spray?

While IV ketamine has certainly proved itself to incredibly effective, what about the more recently approved esketamine nasal spray, Spravato? It turns out, there’s really good data supporting its use as well with a 50% response and 36% remission rate for TRD. Also, repeat dosing does seem to work well for relapse prevention and has been established as safe.

A Look Ahead for Braxia Scientific

The Braxia team is also looking towards classic psychedelics, such as psilocybin, in the management and care of treatment-resistant depression. However, outside of clinical trials, physicians are unable to prescribe the classic 5HT2a psychedelics due to their legal status but hope to expand their treatment toolkit to include them soon. In the meantime, ketamine is showing remarkable efficacy in the treatment of ultra-resistant depression.

Read More

Trending